1. ALLA AKTIER
  2. NYHETER
  3. PROSTALUND

ProstaLund

Nyheter ProstaLund Nyheter alla bolag

New agreement - Aarhus in Denmark starts up with CoreTherm® treatments

ProstaLund has signed an agreement for CoreTherm® treatments with the new customer Aros Privathospital, with placement of the Coretherm® machine at Skebyparken 154, Aarhus Denmark.

ProstaLund has signed an agreement with Aros Privathospital in Denmark. The agreement means that ProstaLund will install the CoreTherm® machine with accessories at the clinic. The first CoreTherm® treatments are planned to be carried out in August 2024.
"We see a continued interest in CoreTherm® treatments in Denmark and it is pleasing news that ProstaLund now exhibits another machine that can help more Danish patients get help with their urination problems" says Anders Kristensson, CEO ProstaLund AB

For further information, please contact:

Anders Kristensson, CEO
Tel. +46 (0) 769 42 12 16
Email: anders.kristensson@prostalund.com

About ProstaLund

ProstaLund AB (publ) is a Swedish medtech company with a headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement. The company has patented the CoreTherm® Concept treatment method, a customised thermal treatment for BPE (Benign Prostatic Enlargement). ProstaLund is listed on Nasdaq First North Growth Market and has approximately 4,000 shareholders. See also - www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

Attachments

New agreement - Aarhus in Denmark starts up with CoreTherm® treatments

Datum 2024-06-24, kl 12:00
Källa MFN
Bifogade filer
New agreement - Aarhus in Denmark starts up with CoreTherm® treatments
Affiliate
200 kr till alla nya kunder! Just nu får alla nya kunder på Nordnet 200 kronor insatta i fonden Nordnet One Offensiv. Erbjudandet gäller mellan 1:e och 30:e september!
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet